Pharmaceutical sector
Pharmaceutical maintenance: one unplanned stop avoided, one batch saved
In pharma, a piece of equipment that fails puts a multimillion-dollar batch at risk and adds to the shortage backlog tracked by regulators. The reliability of your equipment fleet and the speed of your maintenance technicians become the real line of defense for your output. Mimorian equips those technicians to diagnose fast, decide right and hold production availability.
Machine availability is becoming a public-health issue
Over five years, French pharmaceutical production has slipped from the top rank in Europe, held until 2008, to sixth today, while remaining the second-largest player in Europe across 256 GMP-certified sites and more than 109,000 jobs. Over the same period, supply tension has shifted scale: shortage and shortage-risk reports to the French medicines agency (ANSM) rose from 405 in 2016 to 4,925 in 2023.\n\nEquipment availability is moving to the front line, all the more so as pharma plants run at 55-65% machine efficiency against a world-class level above 85%, meaning 15 to 25% of capacity is recoverable with no new investment. At the same time, the skills pool is shrinking: 38.5% of employees are over 50 and more than 80% of manufacturers report a skills gap. Maintenance know-how is retiring just as every stop costs the most.
The equipment fleet to maintain in pharma
Mimorian maintains production equipment, not the pharmaceutical process. The scope is maintenance diagnostics and traceability.
Filling and packaging lines
Sterile filling, capsule and tablet forming, inspection, packaging. A micro-stop on a sterile line has heavy consequences and calls for fast, reliable diagnostics.
Critical process and utilities
Freeze dryers, autoclaves, bioreactors, air handling units, purified water production. This equipment is critical to availability and tightly regulated.
Cleanroom environment
Equipment in controlled-atmosphere zones imposes specific intervention constraints. Having the right machine context before entering the zone saves valuable time.
Your pain points, what maintenance changes
Five concrete situations from the pharmaceutical shop floor, and the lever Mimorian pulls each time, always through maintenance.
These levers build on our AI-guided diagnostics and maintenance know-how capture capabilities, detailed in our reference guides.
Typical rollout: alongside your maintenance, no IT big bang
The first question a plant director asks about a maintenance AI is the integration risk. Mimorian answers with a light rollout, measurable fast, driven by the field.
A ready-to-use SaaS workstation for the technician
Mimorian runs on the technician's device (tablet, smartphone, browser), alongside your current tools. The technician opens it in front of a complex breakdown, talks through it by voice, gets targeted hypotheses and runs the diagnosis. The structured report then flows back into your CMMS by export or API.
First value in two weeks, in a closed loop
The pilot starts on a limited scope: a few sensitive machines, one critical line. An export is enough to start, the connection to your information system comes later, at your pace. The first measurable value lands in two weeks on a real breakdown.
Adoption driven by the field
The technician adopts it because it saves 30 to 45 minutes a day on admin work and makes the job more interesting. Once value is proven on the pilot, the rollout to other lines and sites happens step by step.
3 questions to ask yourself
Does my intervention record hold up in an audit?
A one-line report files the action, not the reasoning. Mimorian builds a structured record as the intervention unfolds: cause, tests, adjustments, return to normal, usable for compliance.
Is AI defensible in a regulated environment?
Explainable, traceable AI supervised by a human is. Mimorian exposes its assumptions and their sources, and the human validates every recommendation. It is the opposite of a black box.
Can I recover capacity without buying new equipment?
Part of the idle capacity is recovered through better reliability and better-run maintenance of the existing fleet. Mimorian speeds up interventions and makes them more reliable, which improves machine availability.
Explore the other sectors
Food & beverage sector
Food & Beverage
Margins at 3.8%, an ageing equipment fleet, frequent stoppages: line availability becomes the nerve of competitiveness.
See the sectorPlastics processing sector
Plastics
An industry that is 80% subcontracting, caught in a margin squeeze, running complex presses: machine availability decides the margin.
See the sectorOil & Gas sector
Oil & Gas
Downtime above $500K/h, an aging offshore fleet, the human factor: maintenance decides availability and safety.
See the sectorAutomotive sector
Automotive
Nearly $2.3M an hour of downtime, French output in decline, seniors leaving: every minute of diagnosis saved counts.
See the sectorSee Mimorian on one of your critical machines
Pick a sensitive machine on your site. We show you the guided diagnostics and the intervention record on a pilot scope of a few weeks.
Sources
- LEEM, The French pharmaceutical market, 2024: France down from 1st (2008) to 6th among European producers, 2nd European player, 256 GMP-certified sites. ↗
- LEEM, Employment in the pharmaceutical industry, 2024: 109,243 jobs, growth slowing from +2.4% (2023) to +1.1% (2024), 38.5% of employees over 50. ↗
- ANSM (open data), stock shortages, 2025: 405 reports in 2016 versus 4,925 in 2023, 3,848 in 2024. ↗
- Siemens / Senseye, The True Cost of Downtime 2024: $1.4 trillion a year in unplanned downtime for the Fortune Global 500, or 11% of revenue versus 8% in 2019. ↗
- iFactory, OEE in Pharmaceutical Manufacturing, 2024 (vendor order-of-magnitude figures): pharma OEE 55-65% versus above 85% at best level, 15 to 25% of capacity recoverable without capex. ↗
- info2soft (source IDS-INDATA / Oxmaint), 2025: up to $9M per batch destroyed after an unplanned production stop. ↗
- INRS / EU-OSHA, maintenance organization, 2024: maintenance accounts for 15 to 20% of workplace accidents and 10 to 15% of fatal accidents. ↗
- INRS / French health insurance / Preventica, machine safety, 2024: machines behind 18% of accidents with more than 4 days off work in chemicals, rubber and plastics. ↗
- McKinsey (via AMS), 2023: more than 80% of pharma manufacturers report a skills gap. ↗
- McKinsey (via Manufacturing Chemist), 2024: predictive maintenance cuts machine downtime by up to 50% and extends machine life by up to 40%. ↗
- FDA (via Certivo), 2025: 105 quality warning letters in 2024 (+11%), 60 to 80% of GMP warning letters citing data integrity. ↗
- Figures shown in USD as reported by each source.